Gornitzky represented the underwriters, led by Jefferies and Barclays, in Alcobra Ltd.’s USD 40 million offering of shares on the NASDAQ Global Market. Alcobra is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (FXS).
Jefferies and Barclays acted as joint book-running managers for the offering. Oppenheimer, Roth Capital and Cantor Fitzgerald acted as co-managers for the offering
The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Avi Meer.
